Boehringer Ingelheim is pumping funds into the still-hot antibody-drug conjugate space, committing 27 million Swiss francs ...

The authors conclude that this advance-the fruit of collaboration between various CNIC groups and laboratories in Germany ... from Fundación "la Caixa", the Boehringer Ingelheim Foundation ...

It is the only LIS instance that comes with a general architecture and also a user interface that both serves and links individual laboratories. Operations can be managed in all testing regions of ...

Boehringer Ingelheim will conduct biophysical and structural studies, including cryo-electron microscopy (cryoEM), on Boehringer pipeline targets enabled by the Salipro ®-technology to identify ...

Northvolt AB today announced that it has filed for bankruptcy in Sweden. It says Northvolt North America is solvent, but what will happen to its massive EV battery plant project in Canada?

Alkem Laboratories Ltd on Wednesday announced the launch of generic empagliflozin and its combinations in India. The formulation will launched under the brand name ‘Empanorm’ at prices that ...

Silicon Labs (NASDAQ: SLAB) is the leading innovator in low-power wireless connectivity, building embedded technology that connects devices and improves lives. Merging cutting-edge technology into ...

(Image Credits: Pixabay) Boehringer Ingelheim’s blockbuster diabetes drug, Empagliflozin, is now off-patent in India, paving the way for domestic drugmakers to launch generic versions.

Top 20 biopharma goes live with Veeva Development Cloud to speed the delivery of treatments for currently incurable diseases "Together with Veeva, Boehringer has advanced its approach to clinical ...

Boehringer Ingelheim and Veeva (VEEV) Systems have announced the launch of Boehringer’s One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They first ...